GRFS Stock Recent News

GRFS LATEST HEADLINES

GRFS Stock News Image - accesswire.com

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

accesswire.com 2024 Aug 07
GRFS Stock News Image - accesswire.com

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

accesswire.com 2024 Aug 06
GRFS Stock News Image - accesswire.com

LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

accesswire.com 2024 Jul 30
GRFS Stock News Image - reuters.com

Spanish pharmaceutical company Grifols said on Tuesday it had revised its financial records between 2020 and 2023 lower by 457 million euros ($494 million) to adjust the value of its stake in Chinese company Shanghai RAAS.

reuters.com 2024 Jul 30
GRFS Stock News Image - accesswire.com

LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

accesswire.com 2024 Jul 29
GRFS Stock News Image - globenewswire.com

BARCELONA, Spain, July 29, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced that the United States Food and Drug Administration (FDA) has approved an expanded label for XEMBIFY®, the company's 20% subcutaneous immunoglobulin (SCIg), to include treatment-naïve patients with primary humoral immunodeficiencies (PI).

globenewswire.com 2024 Jul 29
GRFS Stock News Image - accesswire.com

LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

accesswire.com 2024 Jul 26
GRFS Stock News Image - accesswire.com

LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

accesswire.com 2024 Jul 25
GRFS Stock News Image - accesswire.com

LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

accesswire.com 2024 Jul 24
GRFS Stock News Image - accesswire.com

LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

accesswire.com 2024 Jul 23
10 of 50